BISPECIFIC SINGLE CHAIN FV ANTIBODY MOLECULES AND METHODS OF USE THEREOF

(19)

(11)

EP 1 912 674 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	25.04.2012 Bulletin 2012/17

(45)	Mention of the grant of the patent:
	26.10.2011 Bulletin 2011/43

(21)	Application number: 06784990.1

(22)	Date of filing: 14.06.2006

(51)

International Patent Classification (IPC):

A61K 39/395^(2006.01)
C07K 16/28^(2006.01)

C07K 16/44^(2006.01)

(86)	International application number:
	PCT/US2006/023479

(87)	International publication number:
	WO 2007/084181 (26.07.2007 Gazette 2007/30)

(54)	BISPECIFIC SINGLE CHAIN FV ANTIBODY MOLECULES AND METHODS OF USE THEREOF BISPEZIFISCHE EINZELKETTEN-FV-ANTIKÖRPER-MOLEKÜLE UND ANWENDUNGSVERFAHREN DAFÜR MOLÉCULES D'ANTICORPS FV À CHAÎNE UNIQUE BISPÉCIFIQUES ET PROCÉDÉS D'UTILISATION DE CELLES-CI

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30)

Priority:

15.06.2005 US 154103

(43)	Date of publication of application:
	23.04.2008 Bulletin 2008/17

(60)	Divisional application:
	11177829.6 / 2425850

(73)	Proprietors:
	The Regents of the University of California Oakland, CA 94607-5200 (US) FOX CHASE CANCER CENTER Philadelphia, PA 19111 (US)

(72)	Inventors:
	ADAMS, Gregory, P. Philadelphia, PA 19111 (US) HORAK, Eva, M. West Orange, NJ 07052 (US) WEINER, Louis, M. Philadelphia, PA 19111 (US) MARKS, James, D. Kensington, CA 94707 (US)

(74)	Representative: Roberts, Michael Austin et al
	Greaves Brewster LLP Indigo House Cheddar Business Park Wedmore Road Cheddar, Somerset BS27 3EB Cheddar, Somerset BS27 3EB (GB)

(56)

References cited: :

WO-A-02/00914
US-A- 5 977 322
US-A1- 2002 132 990

WO-A-2004/032961
US-A- 5 990 275
US-A1- 2004 071 696

SCHMIDT M ET AL: "A BIVALENT SINGLE-CHAIN ANTIBODY-TOXIN SPECIFIC FOR ERB-2 AND THE EGF RECEPTOR" INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 65, no. 4, 8 February 1996 (1996-02-08), pages 538-546, XP000646380 ISSN: 0020-7136
DESPLANCQ D ET AL: "Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3" PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 7, no. 8, 1 August 1994 (1994-08-01), pages 1027-1033, XP000445077 ISSN: 0269-2139


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).